A carregar...
Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice
BACKGROUND/OBJECTIVE: Treatment with immune checkpoint inhibitors (ICIs) in oncology patients is increasing. Although ICIs trigger rheumatic immune-related adverse events, development of SLE features has been rare. Whether long-term treatment with ICIs would promote SLE features remains unknown. To...
Na minha lista:
| Publicado no: | Lupus Sci Med |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6519407/ https://ncbi.nlm.nih.gov/pubmed/31168399 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/lupus-2018-000313 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|